DALLAS, April 17, 2019 (GLOBE NEWSWIRE) -- via
OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts,
Inc.) (KALY) (“KALYâ€) today published a
presentation elaborating on the company’s overall strategy to
discover, develop and commercialize novel therapeutics from its
proprietary cannabinoid product platform. KALY owns and
operates a patented cannabis extraction process. Following four
years of research and development, the company recently executed a
strategy to bring the resulting intellectual property (IP) into a
public company as part of a plan to capitalize its next stage of
development. KALY is that public company platform. In
conjunction with that plan, the company has recently disclosed four
of its leading research and development initiatives targeting four
specific health issues:
The presentation below and incorporated into the
company’s website offers further detail on the company’s progress
to date and plans moving forward to commercialize cannabis
therapies.
Patented Cannabis Extracts Targeting $170 Million
Pharmaceutical Treatments
In the fourth quarter of last year, 2018, KALY
acquired NCM Biotech (NCMB). NCMB is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from a proprietary cannabinoid product platform
in a broad range of disease areas. In four years of
operations, the company has established a leading position in the
development of plant-derived cannabinoid therapeutics through a
proven drug discovery and patented development process. The
resulting intellectual property portfolio and the established
regulatory and manufacturing expertise have created a significant
opportunity. KALY, through its subsidiary, NCMB has a deep
pipeline of additional cannabinoid product candidates including
four distinct compounds. KALY has completed the first stage
of clinical development and testing for a Chronic Obstructive
Pulmonary Disease (COPD) therapy and is currently conducting phase
one development and trials for compounds targeting Cancer Pain
Management, Type 2 Diabetes and Epilepsy.
$170 Million Cannabis Therapeutics Market
Opportunity
Cannabis Research Methodology
KALY, through its subsidiary NCMB focuses on the
use of specific cannabis extracts alone, and also along with using
a proprietary process which combines molecules of already proven
therapeutic utility to combat a variety of clinical
disorders. In recognition of the need to standardize
candidate products and to determine mechanisms for action with
scientific credibility, KALY has established collaborations with
other companies and with universities to enhance understanding and
provide scientific support to the introduction of novel cannabis
extract formulations for the consumer marketplace.
KALY has already published its COPD research and initiated a second
stage of research and development. Research reports on the
first phase of development for KALY’s cannabis compounds for Type 2
Diabetes, Cancer Pain Management and Epilepsy are expected to be
published later this year.
To accelerate development, KALY is developing key
partners with an emphasis on establishing joint ventures with
existing biopharmaceutical companies. The company has a $3.5
million development plan for its next stage of development and
management is working diligently to fund that development plan
through the capital structure of partner companies.
Beyond The Initial Four Therapies
Beyond the four specific cannabis therapies
currently in various stages of research and development, KALY has a
number of additional target therapies in its research pipeline.
KALY’s proprietary extracts have been evaluated in a genomic study
where the extracts have exhibited remarkable activity in gene
arrays by up or down regulating individual genes by as much as 200
fold. Genes appearing especially sensitive to the
introduction of KALY’s cannabis extracts were associated with
inflammation, healing and cancer inhibition. The results of
the genomic studies have served to initiate planning for a host of
additional therapies that can be developed from KALY’s proprietary
cannabis extracts.
$1 Million 2019 Revenue Target From Parallel Revenue
Strategy
KALY is not relying on its biopharmaceutical
development strategy alone to insure the company’s long-term
success. With the popularity of cannabis extracts for
infusion into various consumer products, KALY’s patented extraction
process offers arguably the highest quality extract to the infusion
market. Drawing on KALY’s patented cannabis extraction
expertise, Puration’s (PURA) EVERx CBD
Sports Water is already the leading CBD infused beverage for the
sports nutrition market. KALY has also introduced its own CBD
confections line, Hemp4mula with CBD infused gum already on the
market and gummies on the way. Hemp4mula is expected to be
available on the Ecommerce site USMJ.com hosted by
North American Cannabis Holdings, Inc. (USMJ) (aka USMJ). KALY has also entered into
a partnership with Nouveau (NOUV), a
cannabis cultivation company, with plans to develop a proprietary
cannabis cultivar that can further enhance the quality of KALY’s
extracts. KALY’s consumer revenue strategy offers a business
line that can stand alone, but one that also provides KALY with the
long-term staying power to take the necessary time to bring its
cannabis extract biopharmaceutical products to market.
Currently, KALY management anticipates that its $1 million 2019
revenue goal for its parallel consumers market strategy is well
within reach.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459